Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 8;13(3):432.
doi: 10.3390/v13030432.

Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review

Lorenzo Onorato  1 , Mariantonietta Pisaturo  1 , Mario Starace  1 , Carmine Minichini  1 , Alessandra Di Fraia  1 , Roberta Astorri  1 , Nicola Coppola  1
Affiliations
Review

Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review

Lorenzo Onorato et al. Viruses. .

Abstract

The availability of all oral direct acting antiviral agents (DAAs) has revolutionized the management of HCV infections in recent years, allowing to achieve a sustained virological response (SVR) in more than 95% of cases, irrespective of hepatitis C Virus (HCV) genotype or staging of liver disease. Although rare, the failure to the latest-generation regimens (grazoprevir/elbasvir, sofosbuvir/velpatasvir, pibrentasvir/glecaprevir) represents a serious clinical problem, since the data available in the literature on the virological characteristics and management of these patients are few. The aim of the present narrative review was to provide an overview of the impact of baseline RASs in patients treated with the latest-generation DAAs and to analyze the efficacy of the available retreatment strategies in those who have failed these regimens.

Keywords: DAA; RAS; chronic hepatitis C; retreatment; virological failure.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. World Health Organization . Global Hepatitis Report 2017. World Health Organization; Geneva, Switzerland: 2017. - DOI
    1. Spearman C.W., Dusheiko G.M., Hellard M., Sonderup M. Hepatitis C. Lancet. 2019;394:1451–1466. doi: 10.1016/S0140-6736(19)32320-7. - DOI - PubMed
    1. Foreman K.J., Marquez N., Dolgert A., Fukutaki K., Fullman N., McGaughey M., Pletcher M.A., Smith A.E., Tang K., Yuan C.-W., et al. Forecasting life expectancy, years of life lost, and all-Cause and cause-Specific mortality for 250 causes of death: Reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018;392:2052–2090. doi: 10.1016/S0140-6736(18)31694-5. - DOI - PMC - PubMed
    1. World Health Organization . Global Health Sector Strategy on Viral Hepatitis 2016–2021. World Health Organization; Geneva, Switzerland: 2016. Glob Hepat Program Dep HIV/AIDS 2016.
    1. Pawlotsky J.M., Negro F., Aghemo A., Berenguer M., Dalgard O., Dusheiko G., Marra F., Puoti M., Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatol. 2020;73:1170–1218. doi: 10.1016/j.jhep.2020.08.018. - DOI - PubMed

Substances

LinkOut - more resources